TMCI vs. ORGO, SGHT, BVS, ANGO, ESTA, AORT, SILK, BLFS, AVNS, and EYE
Should you be buying Treace Medical Concepts stock or one of its competitors? The main competitors of Treace Medical Concepts include Organogenesis (ORGO), Sight Sciences (SGHT), Bioventus (BVS), AngioDynamics (ANGO), Establishment Labs (ESTA), Artivion (AORT), Silk Road Medical (SILK), BioLife Solutions (BLFS), Avanos Medical (AVNS), and National Vision (EYE). These companies are all part of the "medical" sector.
Organogenesis (NASDAQ:ORGO) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, community ranking, valuation, analyst recommendations, institutional ownership, earnings and risk.
Organogenesis has a net margin of 1.34% compared to Organogenesis' net margin of -27.93%. Treace Medical Concepts' return on equity of 2.11% beat Organogenesis' return on equity.
Organogenesis received 73 more outperform votes than Treace Medical Concepts when rated by MarketBeat users. Likewise, 66.44% of users gave Organogenesis an outperform vote while only 51.06% of users gave Treace Medical Concepts an outperform vote.
49.6% of Organogenesis shares are held by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are held by institutional investors. 34.0% of Organogenesis shares are held by company insiders. Comparatively, 24.4% of Treace Medical Concepts shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Organogenesis has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500. Comparatively, Treace Medical Concepts has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500.
Organogenesis presently has a consensus target price of $4.88, suggesting a potential upside of 50.46%. Treace Medical Concepts has a consensus target price of $12.86, suggesting a potential upside of 66.54%. Given Organogenesis' higher possible upside, analysts plainly believe Treace Medical Concepts is more favorable than Organogenesis.
Organogenesis has higher revenue and earnings than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.
In the previous week, Treace Medical Concepts had 2 more articles in the media than Organogenesis. MarketBeat recorded 4 mentions for Treace Medical Concepts and 2 mentions for Organogenesis. Treace Medical Concepts' average media sentiment score of 1.00 beat Organogenesis' score of 0.56 indicating that Organogenesis is being referred to more favorably in the media.
Summary
Organogenesis beats Treace Medical Concepts on 14 of the 18 factors compared between the two stocks.
Get Treace Medical Concepts News Delivered to You Automatically
Sign up to receive the latest news and ratings for TMCI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TMCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Treace Medical Concepts Competitors List
Related Companies and Tools
